Asarina Pharma ApS: Financial statements 2023
CVR: 38495712
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Asarina Pharma ApS (CVR 38495712) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -884,336 and a net result of DKK -42,903,193 compared with DKK -9,822,821 the year before. Equity in the 2023 report amounted to DKK 1,225,889. The solvency ratio was 49.2%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -884,336
- Profit/Loss
- DKK -42,903,193
- Equity
- DKK 1,225,889
- Total Assets
- DKK 2,490,415
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -884 t. | -42.9 mio. | 1.2 mio. | 1 |
| 2022 | - | -509 t. | -9.8 mio. | 42.7 mio. | 1 |
| 2021 | - | -887 t. | -24.7 mio. | 49 mio. | 1 |
| 2020 | - | -1.9 mio. | -51.5 mio. | 44.1 mio. | 2 |
| 2019 | - | -1.4 mio. | -52.4 mio. | 51.1 mio. | 3 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Asarina Pharma ApS has published its annual report for 2022. Gross profit came to DKK -508,850, and the net result was DKK -9,822,821.
About Asarina Pharma ApS
Asarina Pharma ApS was a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2017. The company has been dissolved on 30 June 2026. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Asarina Danmark ApS. The company has 1 employee (2025). In 2024, the company reported a gross profit of DKK -365,453 and a net result of DKK -1,333,232 compared with DKK -42,903,193 the year before. Equity in the 2024 report amounted to DKK -107,343.